Subcutaneous Fat Density Is an Independent Predictor of Adverse Outcomes and Shows Early Improvement After Liver Transplantation.
Emergingsuggested applicable standard· AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234.
Decision at stakeassessing body composition in liver transplant candidates
No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.
Our full summary of this standard
Refer patients with decompensated cirrhosis (including those with MELD-Na <15 or MELD 3.0 <15 if they have clinically significant portal hypertension, recurrent ascites, hepatic encephalopathy, or variceal bleeding), acute liver failure meeting King's College Criteria/UNOS Status 1A, or HCC within Milan/UCSF criteria for comprehensive multidisciplinary liver transplant evaluation, with MELD 3.0 driving UNOS waitlist allocation and MELD exception scoring for HCC/HPS/FAP. Optimize modifiable risk factors before listing (alcohol abstinence, HCV DAA treatment, vaccinations, DM/obesity/OSA and dental clearance) and use bridging/downstaging locoregional therapy for HCC while awaiting transplant. After transplant, maintain lifelong immunosuppression with tacrolimus plus mycophenolate ± tapered steroids alongside infection prophylaxis and recurrent-disease surveillance.